Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo controlled, phase 2 study of pemetrexed and cisplatin plus enzastaurin versus pemetrexed and cisplatin plus placebo in chemonaive patients with advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer

Next Previous
X
Search
Trial Profile

Randomized, double-blind, placebo controlled, phase 2 study of pemetrexed and cisplatin plus enzastaurin versus pemetrexed and cisplatin plus placebo in chemonaive patients with advanced, unresectable, or metastatic (stage IIIB or IV) non-small cell lung cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzastaurin (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 09 Oct 2020 Status changed from completed to discontinued.
    • 01 Feb 2012 Results published in Oncology.
    • 12 Oct 2009 Tolerability results have been presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top